Cranial Stabilization Devices Market Size is slated to expand substantially between 2023 and 2032 on account of the rapid shift toward minimally invasive neurosurgeries.
Minimally invasive spine surgeries are gaining notable momentum for the treatment of pediatric abnormalities and spinal trauma. Recent advances in cranial fixation and craniomaxillofacial systems will positively steer the industry revenue with the influx of advanced surgical tools and technologies.
For instance, in June 2022, Medtronic announced the 510(k) clearance from the U.S. Food & Drug Administration (FDA) and the Breakthrough Design designation for its first-of-its-kind LigaPASS™ 2.0 Ligament Augmentation System.
Based on product, the cranial stabilization devices market is set to witness an upsurge in demand for brain retractor systems through 2032 owing to their ability to ensure stability during neurosurgeries. The development of highly sophisticated retractors enabling high-quality visualization of tissues will add to the growth of the segment. Meanwhile, skull clamps are poised to secure significant market gains owing to their increasing use during delicate surgeries and craniotomy drilling.
With regards to end-use, hospitals are projected to hold a notable share in the cranial stabilization devices industry by 2032. The growing remuneration from hospitals can be attributed to high patient preference toward these facilities for surgical procedures. Hefty investments in next-generation hospital infrastructures to address the growing burden of neurological diseases and road accidents will boost the adoption of cranial surgery devices across these settings.
For instance, in January 2023, the Government of India, Ministry of State for Education, and the Ministry of External Affairs launched India’s first-ever 100% carbon-neutral hospital backed by an investment of more than USD 145 million from Ambica Medical Foundation & Research Center.
Regionally, the North America cranial stabilization devices market size is poised to amass sizeable remuneration over 2023-2032 driven by the introduction of favorable reimbursement policies and the surging cases of brain cancer. Estimates indicate that the prevalence of primary cancerous tumors of the spinal cord and brain in adults will reach 24,810 in the U.S. in 2023. Meanwhile, more than 5,200 American children under the age of 20 years are expected to be diagnosed with a central nervous system (CNS) tumor in 2023.
The competitive landscape of the global cranial stabilization devices market includes Zimmer Biomet, OsteoMed (Marmon Group), DePuy Synthes (Johnson & Johnson), Jintan Huida Medical Instrument Co. Ltd., Micromar, Pro med instruments, ZheJiang Apeloa JiaYuan Pharmaceutical, Integra LifeSciences Holdings Corporation, Changzhou Huida Medical Equipment, Medtronic, Stryker, and B. Braun Mesulgen AG.